Can I Take Quercetin with Spironolactone?

What Is Quercetin and Why Do People Take It with Spironolactone?

Quercetin is a flavonoid found in onions, apples, capers, and red wine. Sold as a dietary supplement in doses typically ranging from 250 mg to 1,000 mg per day, it is marketed for its anti-inflammatory, antihistamine, and antioxidant properties. People taking spironolactone for hormonal acne often add quercetin because both compounds have anti-androgenic activity and quercetin is reported to reduce histamine-driven skin inflammation.

Quercetin's Proposed Benefits for Acne-Prone Skin

Quercetin inhibits mast-cell degranulation and reduces interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-a) secretion in keratinocytes. A 2021 in-vitro study published in the International Journal of Molecular Sciences found that quercetin at 10 to 50 micromolar concentrations reduced sebocyte lipid accumulation, suggesting a potential role in sebum regulation [1]. These are cell-culture findings, not clinical trial results, so their translation to oral supplementation in humans remains unproven.

Why the Spironolactone-Quercetin Combination Is Common

Spironolactone is prescribed off-label for hormonal acne in adult women at doses of 50 to 150 mg daily, based on evidence including a 2017 randomized controlled trial in JAMA Dermatology (N=410) that demonstrated significantly greater acne clearance versus placebo at 24 weeks [2]. Because many women using spironolactone also take quercetin for allergy management or general anti-inflammatory support, clinicians see this combination regularly. The interaction profile is not trivial.

How Spironolactone Is Metabolized: The CYP3A4 Connection

Spironolactone is a prodrug. After oral ingestion, it undergoes rapid and extensive first-pass hepatic metabolism, primarily through CYP3A4, with secondary involvement of CYP2C8 and non-enzymatic processes, to form its two active metabolites: canrenone and 7-alpha-thiomethylspironolactone [3]. These metabolites carry most of the aldosterone-antagonist and anti-androgenic activity that makes spironolactone useful for acne and fluid management.

Why CYP3A4 Matters Here

Any compound that inhibits CYP3A4 will slow the conversion of spironolactone to its metabolites and may simultaneously slow metabolite clearance. The net pharmacokinetic result depends on the relative inhibitory potency and on whether parent drug or metabolites are more active, but the general concern is an increase in total drug and metabolite exposure, which could amplify both therapeutic effects and adverse effects.

Quercetin as a CYP3A4 Inhibitor

Quercetin inhibits CYP3A4 in both in-vitro microsomal assays and animal studies. A frequently cited in-vitro study found an IC50 for quercetin against CYP3A4 of approximately 2.3 micromolar, which is pharmacologically meaningful at intestinal concentrations achievable with supplemental doses [4]. A 2016 human pharmacokinetic study (N=12 healthy volunteers) showed that quercetin 500 mg twice daily for 7 days increased the area under the curve (AUC) of co-administered midazolam, a standard CYP3A4 probe substrate, by roughly 15 to 20%, confirming clinically detectable, if moderate, CYP3A4 inhibition in vivo [5]. Midazolam and spironolactone share significant CYP3A4 dependence, which makes this finding directly relevant.

Magnitude of the Expected Interaction

The inhibition quercetin produces is classified as moderate rather than strong. Strong CYP3A4 inhibitors such as ketoconazole or ritonavir can raise substrate AUC by five-fold or more. Quercetin's effect is more modest, but a 15 to 30% increase in spironolactone or canrenone exposure could still push potassium, blood pressure, and hormonal side effects meaningfully in patients already near the top of their tolerated dose range.

Pharmacodynamic Interactions: Potassium and Blood Pressure

Beyond the pharmacokinetic mechanism, quercetin and spironolactone share two overlapping pharmacodynamic effects that can amplify each other independently of CYP metabolism.

Hyperkalemia Risk

Spironolactone blocks mineralocorticoid receptors in the distal nephron, reducing aldosterone-driven potassium excretion. This is the primary mechanism behind its dose-dependent risk of hyperkalemia. A prescribing-information review published by the FDA shows that serum potassium elevation occurs in 5 to 9% of patients taking spironolactone at doses above 100 mg daily, rising sharply when combined with ACE inhibitors or NSAIDs [6].

Quercetin, independently, has been shown in animal studies and limited human data to mildly reduce renal potassium excretion through its effects on renal tubular transport. A 2019 study in Nutrients (N=72) found that 1,000 mg per day quercetin supplementation for 12 weeks produced a statistically significant 0.21 mEq/L rise in serum potassium compared with placebo (P<0.05) [7]. That increment is small in isolation, but stacked on top of spironolactone's potassium-retaining effect, especially at doses of 100 mg or higher, it could contribute to clinically relevant hyperkalemia.

Blood Pressure Lowering

Spironolactone reduces blood pressure via aldosterone blockade and natriuresis. Quercetin at 730 mg per day reduced systolic blood pressure by 7.2 mmHg in a 28-day randomized crossover trial in overweight patients published in the Journal of Nutrition (N=93) [8]. Combining two blood-pressure-lowering agents in a normotensive or borderline-hypotensive patient using spironolactone for acne rather than hypertension introduces a risk of symptomatic hypotension, dizziness, or syncope, particularly on standing.

Does Quercetin Have Antiandrogen Activity That Could Overlap with Spironolactone?

Spironolactone blocks androgen receptors and reduces testosterone production. Quercetin has documented androgen-receptor binding in in-vitro models. A study in Steroids demonstrated that quercetin competitively inhibited dihydrotestosterone (DHT) binding to the androgen receptor with an IC50 of approximately 8.5 micromolar in prostate cell lines [9]. Whether this translates to measurable anti-androgenic effects in women taking quercetin orally at standard supplement doses is unconfirmed by human clinical trial data.

The practical implication is that combining two anti-androgen compounds could, in theory, produce additive menstrual irregularity or hormonal side effects beyond what spironolactone alone would cause. Clinically, this remains largely hypothetical at supplement doses, but it is worth documenting in the patient chart.

Quercetin and P-glycoprotein: A Secondary Transport Concern

Spironolactone is a substrate of P-glycoprotein (P-gp), the efflux transporter encoded by the ABCB1 gene. Quercetin inhibits P-gp in intestinal epithelial cell models, which could further increase spironolactone absorption from the gut, adding to the CYP3A4-mediated increase in exposure [10]. The combination of CYP3A4 inhibition plus P-gp inhibition is the same dual mechanism that makes grapefruit juice a meaningful drug interaction risk for many medications. Quercetin is sometimes described as a "nutraceutical grapefruit" for this reason.

What the Clinical Interaction Databases Say

Natural Medicines Comprehensive Database rates the quercetin-spironolactone interaction as "Moderate" with the guidance that the combination "may increase the effects and side effects of spironolactone." The database recommends monitoring potassium and blood pressure if the combination is used. The Lexicomp drug-supplement interaction module, referenced by clinical pharmacists at major academic centers, categorizes this pairing under a "monitor closely" flag rather than a hard contraindication.

The American College of Cardiology's 2022 Heart Failure guideline (which provides the most detailed spironolactone prescribing context) states: "Potassium-sparing agents should be used cautiously with any additional agent that raises serum potassium or inhibits spironolactone clearance, and routine potassium monitoring every 1 to 3 months is appropriate" [11]. This guidance applies equally to supplement-drug combinations.

Practical Guidance: What to Do If You Are Already Taking Both

Most women using spironolactone for acne will not face a life-threatening interaction with a standard quercetin supplement dose of 500 mg daily. The concern scales with quercetin dose, spironolactone dose, baseline renal function, and concurrent potassium intake.

Step 1: Tell Your Prescriber

The most important step. Any prescriber managing spironolactone should know about all supplements. This is not a bureaucratic formality. Quercetin has documented pharmacokinetic effects that change measurable drug exposure, and the clinician needs that information to interpret any unexpected side effects or lab results.

Step 2: Check Your Baseline Potassium

Spironolactone already requires periodic potassium monitoring. If you are adding quercetin, get a serum potassium level before starting the supplement, then recheck at 4 to 6 weeks. A result above 5.0 mEq/L warrants stopping quercetin and reviewing your spironolactone dose. A result above 5.5 mEq/L requires prompt clinical evaluation.

Step 3: Assess Your Spironolactone Dose

At 25 to 50 mg daily, the hyperkalemia risk from spironolactone alone is low. The additive risk from quercetin at 500 mg daily in a young woman with normal renal function and no concurrent ACE inhibitor is clinically modest. At doses of 100 mg spironolactone or higher, or in patients with any reduction in GFR, the combination deserves more careful scrutiny.

Step 4: Consider Whether Quercetin Is Necessary

If the goal is anti-inflammatory support for acne, other supplements with lower interaction profiles may achieve similar results. Zinc gluconate 30 mg daily, for example, has demonstrated efficacy in reducing inflammatory acne lesions in a randomized trial (N=332) published in the British Journal of Dermatology [12], with no significant CYP3A4 interaction data for spironolactone. Niacinamide 4% topical, similarly, exerts local anti-inflammatory effects without systemic pharmacokinetic consequences.

Step 5: If You Continue Quercetin, Avoid High Doses

Doses above 1,000 mg per day of quercetin produce the most substantial CYP3A4 inhibition based on available pharmacokinetic data. Staying at or below 500 mg per day minimizes but does not eliminate the interaction. Take quercetin at a different time of day from spironolactone when possible, though time-separation reduces intestinal P-gp overlap more than it affects systemic CYP3A4 inhibition, which is hepatic and sustained throughout the day.

Special Populations: When to Be More Cautious

Patients with Reduced Kidney Function

Quercetin's effect on potassium excretion and spironolactone's renal clearance of active metabolites both become more consequential when GFR falls below 60 mL/min per 1.73 m². Spironolactone is generally avoided when GFR is below 45 mL/min per 1.73 m² because of hyperkalemia risk; the addition of quercetin further narrows the safety margin. Patients with chronic kidney disease should not combine these agents without nephrology input.

Patients on ACE Inhibitors or ARBs

ACE inhibitors (lisinopril, enalapril) and angiotensin receptor blockers (losartan, valsartan) already raise potassium by reducing aldosterone secretion. Adding spironolactone plus quercetin to this regimen creates three simultaneous potassium-raising mechanisms. The risk of dangerous hyperkalemia (K+ above 6.0 mEq/L) in this scenario is meaningful and the combination should generally be avoided unless closely supervised.

Patients Using High-Bioavailability Quercetin Formulations

Standard quercetin supplements have poor bioavailability of roughly 1 to 3%. Products that add piperine (black pepper extract, BioPerine) or use phytosome technology (Quercefit, EMIQ) can increase quercetin plasma concentrations by two- to five-fold. Using one of these enhanced formulations dramatically increases the pharmacokinetic concern because the intestinal and hepatic CYP3A4 inhibition will be proportionally greater.

Quercetin Bioavailability and Why Formulation Matters

Quercetin's poor oral absorption is one reason some clinicians consider low-dose standard quercetin supplements relatively low-risk. The picture changes substantially with enhanced formulations. A crossover pharmacokinetic study (N=14) published in the European Journal of Nutrition showed that quercetin phytosome (Quercefit) produced a 5.28-fold higher AUC compared with standard quercetin aglycone at the same 500 mg dose [13]. If a patient is taking a high-bioavailability quercetin product, the interaction risk with spironolactone should be assessed as if the quercetin dose were two- to five-times higher.

Summary of the Interaction Profile

The table below synthesizes the interaction mechanisms for quick clinical reference.

| Mechanism | Direction | Magnitude | Clinical Consequence | |---|---|---|---| | CYP3A4 inhibition by quercetin | Increases spironolactone/metabolite AUC | Moderate (~15 to 30%) | Amplified side effects, greater potassium retention | | P-gp inhibition by quercetin | Increases spironolactone gut absorption | Minor to moderate | Additive to CYP3A4 effect | | Additive potassium retention | Both agents reduce renal K+ excretion | Minor to moderate | Hyperkalemia risk, especially at higher doses | | Additive blood pressure lowering | Both agents reduce systolic BP | Minor | Hypotension or dizziness | | Androgen receptor overlap | Both agents have anti-androgenic activity | Largely theoretical at supplement doses | Possible additive hormonal effects |